Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2025-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "康芝药业股份有限公司2025 年半年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2025 Semi-Annual Report Full Text." It explicitly states it is a semi-annual report for the period 2025. The content includes detailed financial data, management discussion and analysis, company business overview, industry analysis, and operational details. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial statements and analysis. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
关于将部分自用房地产转为投资性房地产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding the conversion of some self-used real estate into investment property. It includes details about the properties, accounting treatment, board and supervisory opinions, and meeting resolutions. The document is relatively short (2039 characters) and does not contain comprehensive financial statements or detailed financial performance data. It is a corporate announcement about a specific asset reclassification and related board approvals, not a full financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a regulatory certification or insider dealing report. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a corporate decision and asset reclassification that does not fit other specific categories.
2025-08-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the approval of the company's 2025 semi-annual report and other related matters. It states that the semi-annual report and other detailed reports are published separately on the official disclosure website (cninfo.com.cn). The document itself does not contain the full semi-annual report or detailed financial data but rather announces the approval and references where the full reports can be found. The document length is short (1653 characters) and fits the pattern of an announcement rather than the report itself. Therefore, according to the 'Menu vs Meal' rule, this is a Regulatory Filing (RNS) as it is an announcement of the approval of the report and related resolutions, not the report itself.
2025-08-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 20th meeting of the 6th Board of Directors of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) held on August 26, 2025. It includes approval of the company's 2025 semi-annual report and its summary, a special report on non-recurring fund occupation and related party transactions, and decisions regarding the reclassification and leasing of certain real estate assets. The document states that the semi-annual report and other detailed disclosures are available on the official disclosure website and newspapers, indicating this document itself is not the full semi-annual report but an announcement of board resolutions related to it. The document length is about 2052 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on board meeting decisions rather than detailed financial data or management discussion. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions and related corporate governance decisions.
2025-08-27 Chinese
关于公司2025年半年度非经常性资金占用及其他关联资金往来情况的专项报告
Audit Report / Information Classification · 95% confidence The document is a specialized report from 康芝药业股份有限公司 regarding the company's non-operating fund occupation and other related party fund transactions for the half-year period of 2025. It includes detailed tables of fund balances, transactions, and related party relationships. The document references regulatory guidelines for listed companies' fund transactions and external guarantees. It is a specific financial disclosure related to non-operating fund usage and related party transactions for a half-year period, but it is not a full interim or annual financial report. It is a standalone specialized report focusing on a particular regulatory compliance aspect rather than comprehensive financial statements or management discussion. Therefore, it fits best under Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles or regulatory compliance reports excluding full annual or interim reports. The document length is 2864 characters, which is relatively short but contains substantive financial data specific to regulatory requirements, not just an announcement or certification. Hence, it is not RPA or RNS. H1 2025
2025-08-27 Chinese
北京大成（海口）律师事务所关于康芝药业股份有限公司2024年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2024 Annual General Meeting (AGM) of 康芝药业股份有限公司. It details the procedures for convening and holding the AGM, the qualifications of attendees, the proposals considered, the voting procedures, and the voting results. The document focuses on the legality and validity of the AGM process and the voting outcomes. It does not contain the full annual report or financial statements but rather confirms the legality and results of the shareholder meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which includes official results from shareholder votes at any general meeting. The document length (7533 characters) and content confirm it is not merely an announcement of a report but a detailed legal opinion on the AGM and voting results. Therefore, the correct classification is DVA with high confidence.
2025-06-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.